替加环素血药浓度监测与不良反应的关联性分析

吴诗雅 ,  刘晓丹 ,  胡妍 ,  林琦

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1238 -1248.

PDF (949KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1238 -1248. DOI: 10.12092/j.issn.1009-2501.2026.09.010

替加环素血药浓度监测与不良反应的关联性分析

作者信息 +

Correlation analysis between tigecycline therapeutic concentration monitoring and adverse reactions

Author information +
文章历史 +
PDF (970K)

摘要

目的: 建立人血浆中替加环素的高效液相色谱-串联质谱(HPLC-MS/MS)测定方法,用于研究患者体内的药代动力学特征,并探讨其血药浓度与药物诱导性肝损伤及凝血功能障碍的相关性。方法: 采用蛋白沉淀法处理血浆,以 Eclipse Plus C18 柱分离,0.1% 甲酸水-甲醇梯度洗脱,利血平为内标,流速 0.3 mL/min,正离子模式检测并考察方法各项性能。随后,收集 2024 年 6 月至 2025 年 6 月期间使用替加环素患者的临床资料与血浆样本(n=72)。根据是否发生不良反应(ADR)分组,比较两组血药浓度差异,采用受试者工作特征曲线(ROC)分析确定 ADR 发生的血药浓度折点,并计算敏感度、特异度及曲线下面积(AUC)。结果: 所建方法线性范围为 50~5 000 ng/mL,精密度、准确度及稳定性值均小于 10%,满足临床检测要求。通过 ROC 曲线得到替加环素导致肝损伤的折点为 515.34 ng/mL,致凝血功能障碍的折点为 243.59 ng/mL。结论: 成功建立人血浆中替加环素的 HPLC-MS/MS 方法,替加环素的血药浓度与导致肝损伤及凝血功能障碍有关,建议临床上应联合血药浓度与肝功能、凝血指标监测以守护用药安全。

Abstract

AIM: To establish a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for the determination of tigecycline in human plasma, which was used to study the pharmacokinetic profile in patients and to investigate the correlation between its blood concentration and drug-induced hepatic injury and coagulation dysfunction. METHODS: Plasma was processed by protein precipitation, separated on an Eclipse Plus C18 column, eluted by a 0.1% formic acid water-methanol gradient, with Reserpine as an internal standard, at a flow rate of 0.3 mL/min and detected in the positive ion mode and examined the method properties. Subsequently, clinical data with plasma samples were collected from patients using tigecycline between June 2024 and June 2025 (n=72). The groups were grouped according to whether or not an adverse reaction (ADR) occurred, the differences in blood concentrations between the two groups were compared, and the blood concentration breakpoints at which ADRs occurred were determined using subject's work characterization curve (ROC) analysis, and the sensitivity, specificity, and area under the curve (AUC) were calculated. RESULTS: The linear range of the proposed method was 50-5 000 ng/mL, and the precision, accuracy and stability values were less than 10%, which met the requirements of clinical testing. The ROC curve showed that the fold point of tigecycline causing liver injury was 515.34 ng/mL, and that of coagulation dysfunction was 243.59 ng/mL. CONCLUSION: The HPLC-MS/MS of tigecycline in human plasma was successfully established, and the tigecycline blood concentration is related to the cause of liver injury and coagulation dysfunction. It is recommended that blood concentration monitoring combined with liver function and coagulation indicators should be applied clinically to ensure medication safety.

关键词

替加环素 / 血药浓度监测 / HPLC-MS/MS / 药代动力学 / 肝损伤 / 凝血功能障碍

Key words

tigecycline / therapeutic drug monitoring / HPLC-MS/MS / pharmacokinetics / liver injury / coagulation-disorders

引用本文

引用格式 ▾
吴诗雅,刘晓丹,胡妍,林琦. 替加环素血药浓度监测与不良反应的关联性分析[J]. 中国临床药理学与治疗学, 2026, 31(9): 1238-1248 DOI:10.12092/j.issn.1009-2501.2026.09.010

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Mohamed RAE, Moustafa NM, Mahmoud FM, et al. Whole-genome sequencing of two multidrug-resistantAcinetobacter baumannii strains isolated from a neonatal intensive care unit in Egypt: a prospective cross-sectional study[J].BMC Microbiol, 2024, 24: 362.

[2]

Korczak L, Majewski P, Rombel K, et al. In vitro evaluation of tigecycline synergy testing with nine antimicrobial agents against Enterobacter cloacae clinical strains[J].Front Microbiol, 2024, 15: 1490032.

[3]

Fan XY, Jiang Y, Wu H, et al. Distribution and spread of tigecycline resistance gene tet(X4) in Escherichia coli from different sources[J].Front Cell Infect Microbiol, 2024, 14: 1399732.

[4]

Shi X, Lao D, Xu Q, et al. A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale[J].BMC Infect Dis, 2022, 22: 368.

[5]

Li M, He J, Dong G, et al. Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients[J].J Antimicrob Chemother, 2025, 80(1): 200-208.

[6]

Shi X, Zuo C, Yu L, et al. Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM[J].Front Pharmacol, 2021, 12: 761167.

[7]

Ma C, Ren X, Pang N, et al. Incidence, characteristics, and risk factors of hypofibrinogenemia induced by generic tigecycline: a retrospective study[J].Naunyn Schmiedebergs Arch Pharmacol, 2025, 398(3): 2717-2727.

[8]

Qian Z, Jine W, Hui L, et al. Risk factors for tigecycline-induced hypofibrinogenaemia[J].J Clin Pharm Ther, 2020, 45(6): 1434-1441.

[9]

Cui N, Cai H, Li Z, et al. Tigecycline-induced coagulopathy: a literature review[J].Int J Clin Pharm, 2019, 41(6): 1408-1413.

[10]

Yu M, Wu S, Qi B, et al. Rational use of tigecycline and tigecycline blood concentration monitoring in patients with severe infection[J].Biomed Rep, 2023, 19(2): 51.

[11]

Wang C, Luo B, Liu W, et al. Development and clinical utility of an ultra performance liquid chromatography-tandem mass spectrometry assay for monitoring omadacycline and tigecycline in severe bacterial infections[J].J Mass Spectrom Adv Clin Lab, 2024, 34: 46-54.

[12]

Galvidis IA, Surovoy YA, Tsarenko SV, et al. Tigecycline immunodetection using developed group-specific and selective antibodies for drug monitoring purposes[J].Biosensors, 2023, 13(3): 343.

[13]

Atallah E, Wooten JW, Orman OC, et al. Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study[J].JHEP Rep, 2023, 5(10): 100851.

[14]

Ciricillo J, Myer A, Yeboah-Korang AY, et al. Improving the diagnostic accuracy of RECAM in North American patients with suspected idiosyncratic drug-induced liver injury[J].Am J Gastroenterol, 2025, 120(6): 1325-1333.

[15]

Mahdavijalal M, Petio C, Staffilano G, et al. Innovative solid-phase extraction strategies for improving the advanced chromatographic determination of drugs in challenging biological samples[J].Molecules, 2024, 29(10): 2278.

[16]

Paul R, Ostermann E, Wei Q. Advances in point-of-care nucleic acid extraction technologies for rapid diagnosis of human and plant diseases[J].Biosens Bioelectron, 2020, 169: 112592.

[17]

Ruiz J, Ramirez P, Villarreal E, et al. Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections[J].SAGE Open Med, 2020, 8: 2050312120958897.

[18]

Liu YX, Le KJ, Shi HY, et al. Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review[J].Transl Androl Urol, 2021, 10(1): 292-299.

[19]

Chen Z, Shi X.Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens[J].Medicine (Baltimore), 2018, 97(38): e12467.

[20]

Guo M, Liang J, Li D, et al. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database[J].Thromb J, 2022, 20(1): 12.

[21]

Lei Z, Chen X, Pan F, et al. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies[J].Front Pharmacol, 2023, 14: 1182644.

[22]

Leng B, Xue YC, Zhang W, et al. A retrospective analysis of the effect of tigecycline on coagulation function[J].Chem Pharm Bull, 2019, 67(3): 258-264.

[23]

Yu Z, Zhao Y, Jin J, et al. Prevalence and risk factors of tigecycline-induced liver injury: a multicenter retrospective study[J].Int J Infect Dis, 2022, 120: 59-64.

[24]

Jiang T, He X, Li Q, et al. Risk factors for tigecycline-associated hepatotoxicity in patients in the intensive care units of two tertiary hospitals: a retrospective study[J].J Clin Pharmacol, 2022, 62(11): 1426-1434.

[25]

Liu J, Yan Y, Zhang F.Risk factors for tigecycline-associated hypofibrinogenemia[J].Ther Clin Risk Manag, 2021, 17: 325-332.

[26]

Guo J, Wang S, Zhou M, et al. Nomogram for the prediction of tigecycline-induced hypofibrinogenaemia in a Chinese population[J].Int J Antimicrob Agents, 2024, 63(2): 107062.

[27]

Su W, Song S, Liu J, et al. Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling[J].Front Pharmacol, 2024, 15: 1342947.

[28]

Taubert M, Wicha SG, Frey OR, et al. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study[J].Crit Care, 2018, 22(1): 341.

[29]

Burón C, Hernández M, Cazorla M, et al. Tigecycline population pharmacokinetics in critically ill patients with decompensated cirrhosis and severe infections[J].J Antimicrob Chemother, 2022, 77(5): 1332-1338.

[30]

Zhou CC, Huang F, Zhang JM, et al. Population pharmacokinetics of tigecycline: a systematic review[J].Drug Des Devel Ther, 2022, 16: 1885-1896.

[31]

Cojutti P, Giangreco M, Isola M, et al. Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis[J].Int J Antimicrob Agents, 2017, 50(1): 23-28.

[32]

Misaka S, Maejima Y, Shimomura K.Limited sampling strategy for predicting the area under plasma concentration-time curve of nadolol in healthy subjects[J].J Clin Pharmacol, 2024, 65(5): 621-627.

[33]

Chen Q, Thompson J, Hu Y, et al. High-dose metformin treatment to inhibit complex I during early reperfusion protects the aged mouse heart via decreased mitochondrial permeability transition pore opening[J].J Pharmacol Exp Ther, 2024, 392(3): 100529.

基金资助

福建省自然科学基金(2024J011468)

莆田学院院校联合基金重点项目(2024107)

AI Summary AI Mindmap
PDF (949KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉